Benralizumab (Fasenra®)

Covers Fasenra (benralizumab) as add‑on maintenance therapy for patients ≥12 years with severe eosinophilic asthma (not covered for non‑FDA indications or <12 years). Key requirements: blood eosinophils ≥150 cells/µL within 6 weeks (or prior to another eosinophil‑lowering mAb), ≥3 months of prior inhaled corticosteroid plus another controller, objective evidence of uncontrolled asthma, prescription by/consult with an allergist/immunologist/pulmonologist; initial approval 6 months, reauthorization after ≥6 months for 12 months requires continued ICS use and documented clinical response, dosing per label 30 mg SC q4 weeks ×3 then q8 weeks.

"Fasenra is indicated for the add-on maintenance treatment of pateints with severe asthma aged 12 years and older with an eosinophilic phenotype."

Sign up to see full coverage criteria, indications, and limitations.